Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00019994 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019994 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | Immunization of Patients With Metastatic Melanoma Using a Class II Restricted Peptide From the GP100 Antigen and Class I Restricted Peptides From the GP100 and MART-1 Antigens |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MART-1 antigen, aldesleukin, gp100 antigen, incomplete Freund's adjuvant |
| Start date | Oct 1, 1999 |
| Completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: